



VIA HAND DELIVERY July 16, 2004

Docket No.: PF187D1C1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Li et al.

Application No.: 10/006,394

Confirmation No.: 8404

Filed: December 10, 2001

Art Unit: 1646

For: Human G-Protein Receptor HIBEF51

Examiner: M. Brannock

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-BA listed on the attached Form PTO/SB/08. A copy of reference AC is enclosed.

Copies of references AA-AB, AD-AL, AN, AQ-AS, AV, and AZ-BA were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application No. 09/228,420, filed January 12, 1999, to which the instant application claims priority under 35 U.S.C. § 120; and copies of references AM, AO, AP, AJ, AT, AX, and AY were submitted by Applicants or cited by the Examiner in connection with grandparent application, U. S. Patent Application No. 08/465,971 (now U.S. Patent No. 5,942,414), filed June 6, 1995. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the above-listed files for copies of references AA-AB, and AD-BA.

Applicants also wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA of this application are related to SEQ ID NOS:16401 and 21801 in copending U.S. Patent Application Serial No. 09/912,292. A legible copy of the portions of U.S. Patent Application Serial Nos. 09/912,292 which caused it to be listed on the attached revised form PTO/SB/08 is submitted herewith as reference AC.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.


Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over the listed documents should they be applied as a reference against the claims of the subject application.


Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Dated: July 16, 2004

Respectfully submitted,

By 
Mark J. Hyman
Registration No.: 46,789
HUMAN GENOME SCIENCES, INC.
14200 Shady Grove Road
Rockville, Maryland 20850
(240) 314-1224



JUL 16 2004

Please type a plus sign (+) inside this box → +

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/006,394
Filing Date	June 21, 2002
First Named Inventor	Li et al.
Group Art Unit	1646
Examiner Name	Brannock, M.
Attorney Docket Number	PF187D1C1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (<i>if known</i>)			
	AA	5,155,218	10-13-1992	Weinshank et al.	
	AB	5,942,414	08-24-1999	Li et al.	
	AC	09/912,292	NOT PUBLISHED	Rosen et al.	Pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NOS: 16401 and 21801

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴ (if known)	Kind Code ⁵			
	AD	WO	94/21660		Merck & Co., Inc.	09-29-1994	
	AE	WO	94/05695		New York University	03-17-1994	
	AF	WO	93/07294		NIH	04-15-1993	
	AG	WO	93/12134		Harvard College	06-24-1993	
	AH	WO	92/01810		BRL Screening, Inc.	02-06-1992	
	AI	EP	0590721	A1	Enichem, S.P.A.	04-06-1994	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AJ	GENBANK Accession No. R17870, "yg10d01.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:31997 5' similar to SP:B2AR_MESAU P04274 BETA-2 ADRENERGIC ;, mRNA sequence," (April 1995).	
	AK	GENBANK Accession No. P04274, "Beta-2 adrenergic receptor (Beta-2 adrenoceptor) (Beta-2 adrenoreceptor)," (March 1995).	
	AL	GENBANK Accession No. R43119, (May 1995).	
	AM	EVA, C. et al., "Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family," FEBS Letters 271:81-4 (1990).	
	AN	FARGIN, A. et al., "The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor," Nature 335:358-60 (1988).	

Examiner Signature	Date Considered
--------------------	-----------------

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet	2	of	2	Application Number	10/006,394
				Filing Date	June 21, 2002
				First Named Inventor	Li et al.
				Group Art Unit	1646
				Examiner Name	Brannock, M.
				Attorney Docket Number	PF187D1C1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	AO	FRASER, C.M. et al., "Cloning, sequence analysis, and permanent expression of a human alpha 2-adrenergic receptor in Chinese hamster ovary cells. Evidence for independent pathways of receptor coupling to adenylate cyclase attenuation and activation," J. Biol. Chem. 264:11754-11761 (1989). T ²
	AP	HLA, T. et al., "An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors," J. Biol. Chem. 265(16):9308-13 (1990).
	AQ	KOBILKA, B.K. et al., "cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor," Proc. Natl. Acad. Sci. 84 :46-50 (1987).
	AR	KOBILKA, B.K. et al., "Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor," Science 238:650-6 (1987).
	AS	LEE et al., Drug News and Perspectives 6(7):488-97 (1993).
	AT	LIBERT, F. et al., "Selective amplification and cloning of four new members of the G protein-coupled receptor family," Science 244:569-72 (1989).
	AU	MEYERHOF, W. et al., "Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis," FEBS Letters 284(2):155-60 (1991).
	AV	O'DOWD, B.F. et al., "Cloning and chromosomal mapping of four putative novel human G-protein-coupled receptor genes," Gene 187:75-81 (1997).
	AW	OLIVEIRA et al., J. Computer-Aided Molecular Design 7:649-58 (1993).
	AX	PEPPERL, D.J. et al., CRC Press, 45-6 (1994).
	AY	ROSS, P.C. et al., "RTA, a candidate G protein-coupled receptor: cloning, sequencing, and tissue distribution," Proc. Natl. Acad. Sci. 87:3052-6 (1990).
	AZ	SAMBROOK et al., "Molecular Cloning: A Laboratory Manual," Cold Spring Press (1989).
	BA	YOSHIMATSU T. et al., "Control of gene expression by artificial introns in <i>Saccharomyces cerevisiae</i> ," Science 244:1346-8 (1988).

Examiner Signature	Date Considered
--------------------	-----------------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.